The Wegovy maker says the telehealth company didn't stop selling compounded versions of the blockbuster drug after Novo ...

While positive, results from a late-stage clinical trial appear to be raising questions about how useful the company’s ...

GLP-1 therapies primarily use single-use injectable pens, contributing to medical waste challenges. The pharmaceutical ...

The clearance ushers in a closely-watched launch for Gilead, which aims to show a long-acting injection can upend a market ...

The deal centers around a medicine that could “shift the treatment paradigm for cardiovascular disease,” Lilly said, but also ...

The abrupt termination of the 17 panelists guiding the CDC’s vaccine recommendations could yield a new committee more aligned ...

A new pilot program announced by FDA Commissioner Martin Makary would award vouchers that could cut drug reviews to one or ...

With backers such as Regeneron’s venture arm, Actio Biosciences is working on medicines that counter a wide range of ...

The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, ...

The funds will support Phase 2 testing of a drug the company believes to be able to safety home in on AMPA receptors, an ...

A “heavy workload” and “limited resources” have left the agency unable to meet a June 17 deadline to approve a therapy ...

While the results were an important proof point for so-called anti-myostatin drugs, Scholar Rock executives indicated the ...